Authored by James Sheppard
At the beginning of 2013 Liftstream profiled 13 life science leaders we believed were going to make an impact over the course of the year. Below we outline how Dr Dalvir Gill performed for TransCelerate in 2013.
2013 Liftstream Analysis: Dalvir Gill was appointed the CEO of TransCelerate the non-profit drug discovery organisation. Dr Gills challenge to help simplify the drug development process through a number of initiatives. One of Gill’s challenges in 2013 will be to ensure all the stakeholders of TransCelerate remain supportive of the non-profit’s objective s.
• Harmonise the various goals of the stakeholders
• Advance the company’s various initiatives
• Raise the global profile of TransCelerate Biopharma.
2014 Liftstream Verdict: TransCelerate hit a number of major milestones in 2013 these included the development of a Common Clinical-Trial Protocol across the industry, special population clinical trial networks, investigator registry and a comparator network for clinical trials. In TransCelerate’s first year Mr Gill has made admirable strides with existing stakeholders and added more influential companies such as Astellas, Biogen IDEC and Onyx Pharmaceuticals taking total membership to 16 companies. A year where the main objectives were largely achieved for Dr Gill and TransCelerate.
To see how the other leaders profiled in Liftstream’s 13 for 2013 performed please click here. Liftstream would very much like to hear your thoughts on how you believe these life science leaders performed in 2013. Please leave your comments below, email firstname.lastname@example.org or tweet @liftstream #LSL13for13
Liftstream is an executive search and interim management recruitment company working exclusively within the global life sciences sector.